Josh Riggs - 09 Jun 2023 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
CEO and President, Director
Signature
/s/ Josh Riggs
Issuer symbol
OCX
Transactions as of
09 Jun 2023
Net transactions value
$0
Form type
4
Filing time
13 Jun 2023, 16:05:32 UTC
Previous filing
28 Feb 2023
Next filing
17 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +350,000 $0.000000 350,000 09 Jun 2023 Common Stock 350,000 $0.2132 Direct F1
transaction OCX Option to Purchase Common Stock Award $0 +800,000 $0.000000 800,000 09 Jun 2023 Common Stock 800,000 $0.2132 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options will vest and thereby be exercisable after one year of continuous service from the effective date of grant, and the balance will vest and thereby be exercisable in 36 equal monthly installments commencing one year after the date of grant, subject to continuous service through the applicable vesting date.
F2 The options will vest and thereby be exercisable on December 31, 2025, based on achievement of certain specified targets with respect to the 30-day volume-weighted average price of Company's common stock, measured as of the end of each full calendar month up through December 31, 2025, subject to continuous services through December 31, 2025.